Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV (NCT06233331)
Phase I Dose Escalation Study of the Use of ACU-D1, a Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to test the maximum tolerated dose of ACU-D1 in HIV-positive people with HPV-associated vulvar and perianal lesions. The main questions it aims to answer are: * The maximum tolerated dose of ACU-D1 * Safety and tolerability of topical ACU-D1 * Whether topical ACU-D1 induces p53 and p53-mediated downstream signaling (including p21 induction) in HPV-related lesions * Whether topical ACU-D1 enhances markers of immunity in HPV-infected HIV-positive individuals Participants will be asked * To apply ACU-D1 on the lesions twice daily for 4 weeks * 3 biopsies will be performed at the screening and 3 at the end of 4 weeks.
Who can join: Review the eligibility criteria below.
Location: Grady Memorial Hospital — Atlanta, Georgia
Age range: 21 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Grady Memorial Hospital — Atlanta, Georgia
📞 Contact the Study Coordinator
Phone: (678) 596-3554
Email: Lflowe2@emory.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Human Papilloma Virus
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers — Chicago, Illinois
- Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study — Albany, Georgia
- Impact of Standing Orders Optimization — Chapel Hill, North Carolina
- Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old — Boston, Massachusetts
- Impact of Financial Incentives — Chapel Hill, North Carolina
- Single Visit Clinical Validation of ScreenFire, a Low-cost HPV Test — San Salvador,
Explore by condition: All Human Papilloma Virus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.